134 related articles for article (PubMed ID: 22170289)
1. Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
Taft F; Harmrolfs K; Nickeleit I; Heutling A; Kiene M; Malek N; Sasse F; Kirschning A
Chemistry; 2012 Jan; 18(3):880-6. PubMed ID: 22170289
[TBL] [Abstract][Full Text] [Related]
2. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
3. The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
Eichner S; Knobloch T; Floss HG; Fohrer J; Harmrolfs K; Hermane J; Schulz A; Sasse F; Spiteller P; Taft F; Kirschning A
Angew Chem Int Ed Engl; 2012 Jan; 51(3):752-7. PubMed ID: 22135226
[No Abstract] [Full Text] [Related]
4. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates.
Canal F; Vicent MJ; Pasut G; Schiavon O
J Control Release; 2010 Sep; 146(3):388-99. PubMed ID: 20621587
[TBL] [Abstract][Full Text] [Related]
5. Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach.
Mancuso L; Knobloch T; Buchholz J; Hartwig J; Möller L; Seidel K; Collisi W; Sasse F; Kirschning A
Chemistry; 2014 Dec; 20(52):17541-51. PubMed ID: 25346489
[TBL] [Abstract][Full Text] [Related]
6. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid.
Vlahov IR; Vite GD; Kleindl PJ; Wang Y; Santhapuram HK; You F; Howard SJ; Kim SH; Lee FF; Leamon CP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4578-81. PubMed ID: 20594844
[TBL] [Abstract][Full Text] [Related]
7. Semisynthetic maytansine analogues for the targeted treatment of cancer.
Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
[TBL] [Abstract][Full Text] [Related]
8. A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting.
Wang LL; Balakrishnan A; Bigall NC; Candito D; Miethe JF; Seidel K; Xie Y; Ott M; Kirschning A
Chemistry; 2017 Feb; 23(10):2265-2270. PubMed ID: 27935144
[TBL] [Abstract][Full Text] [Related]
9. Chemoenzymatic approaches toward dechloroansamitocin P-3.
Meyer A; Brünjes M; Taft F; Frenzel T; Sasse F; Kirschning A
Org Lett; 2007 Apr; 9(8):1489-92. PubMed ID: 17378571
[TBL] [Abstract][Full Text] [Related]
10. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
11. A new antitumour ansamitocin from Actinosynnema pretiosum.
Wei GZ; Bai LQ; Yang T; Ma J; Zeng Y; Shen YM; Zhao PJ
Nat Prod Res; 2010 Jul; 24(12):1146-50. PubMed ID: 20582809
[TBL] [Abstract][Full Text] [Related]
12. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
14. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
15. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
17. Targeting the folate receptor (FR): imaging and cytotoxicity of ReI conjugates in FR-overexpressing cancer cells.
Viola-Villegas N; Rabideau AE; Cesnavicious J; Zubieta J; Doyle RP
ChemMedChem; 2008 Sep; 3(9):1387-94. PubMed ID: 18651631
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro/in vivo evaluation of 99mTc-labeled folate conjugates for folate receptor imaging.
Lu J; Pang Y; Xie F; Guo H; Li Y; Yang Z; Wang X
Nucl Med Biol; 2011 May; 38(4):557-65. PubMed ID: 21531293
[TBL] [Abstract][Full Text] [Related]
19. Folate-maytansinoids: target-selective drugs of low molecular weight.
Ladino CA; Chari RV; Bourret LA; Kedersha NL; Goldmacher VS
Int J Cancer; 1997 Dec; 73(6):859-64. PubMed ID: 9399666
[TBL] [Abstract][Full Text] [Related]
20. Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry.
Liu Z; Floss HG; Cassady JM; Chan KK
J Mass Spectrom; 2005 Mar; 40(3):389-99. PubMed ID: 15674857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
